Search

Displaying results 5781 - 5790 of 10000 in total
  1. Drug

    D-JNKI-1

    go.drugbank.com/drugs/DB05660
    Investigational

    organ of Corti during times of oxidative stress. … A synthetic, cell permeable peptide that blocks the MAPK-JNK signal pathway; has potential therapeutic value for long-term protection of both the morphological integrity and physiological function of the

  2. Drug

    PMI-001

    go.drugbank.com/drugs/DB05730
    Experimental

    It is an extract of the roots of an undisclosed perennial shrub which interferes with the production of IL-2 and COX-2 proteins, for the potential treatment of autoimmune diseases, such as rheumatoid arthritis

  3. Drug

    SLx-4090

    go.drugbank.com/drugs/DB05678
    Investigational

    SLx-4090 is a microsomal triglyceride transfer protein (MTTP) inhibitor potentially for the treatment of type 2 diabetes. [A33218]

  4. Drug

    DCLL-9718S

    go.drugbank.com/drugs/DB17392
    Investigational

    DCLL9718S is under investigation in clinical trial NCT03298516 (A Study of DCLL9718S in Participants With Relapsed or Refractory Acute Myeloid Leukemia (AML) or DCLL9718S in Combination With Azacitidine

    Synonyms: THIOMAB antibody drug conjugate comprised of humanized IgG1 anti-C-type lectin-like molecule-1 monoclonal antibody and DNA alkylating cross-linking agent pyrrolo [2,1-c][1,4] benzodiazepine dimer
  5. Drug

    Bleomycin A6

    go.drugbank.com/drugs/DB12992
    Investigational

    The development of this drug, apparently, was discontinued. … This drug participated in clinical trials for the treatment of Squamous Cell Lung Cancer.

  6. Drug

    IN01

    go.drugbank.com/drugs/DB16434
    Experimental

    The study will explore the effect of this vaccine on pulmonary function, oxygen saturation, quality of life, and fibrosing status in addition to biomarkers and molecular markers of the vaccine. … Administration of the vaccine stimulates the production of anti-epidermal growth factor (anti-EGF) neutralizing antibodies[L30543].

  7. Drug

    Navocaftor

    go.drugbank.com/drugs/DB19039
    Investigational

    Navocaftor is under investigation in clinical trial NCT04853368 (Study to Evaluate Adverse Events and Change in Disease Activity With Oral Capsules of Galicaftor/navocaftor/abbv-119 or Galicaftor/navocaftor

  8. Drug

    Contusugene ladenovec

    go.drugbank.com/drugs/DB05322
    Investigational

    Advexin is a well-tolerated and efficacious treatment for numerous cancers, both as monotherapy and in combination with radiation and/or chemotherapy agents.

  9. Drug

    CLX-0921

    go.drugbank.com/drugs/DB05854
    Experimental

    CLX-0921 has a spectrum of activity that differs from commercially available thiazolidinediones. This substance targets the protein peroxisome proliferator-activated receptor gamma.

  10. Drug

    Faropenem medoxomil

    go.drugbank.com/drugs/DB05659
    Investigational

    The prodrug form of faropenem offers dramatically improved oral bioavailability and leads to higher systemic concentrations of the drug. … Faropenem medoxomil is an ester prodrug derivative of the beta-lactam antibiotic [faropenem].